A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Joyce F. Liu, William Thomas Barry, Robert Michael Wenham, Andrea Elisabeth Wahner Hendrickson, Deborah Kay Armstrong, Nancy Chan, David E. Cohn, Jung-min Lee, Richard T. Penson, Mihaela C. Cristea, James L. Abbruzzese, KOJI MATSUO, Alexander Olawaiye, Sarah Farooq, Elizabeth M. Swisher, Eliezer Mendel Van Allen, Geoffrey Shapiro, Elise C. Kohn, S. Percy Ivy, Ursula A. Matulonis
Institutions: Dana-Farber Cancer Institute, Moffitt Cancer Center, Mayo Clinic, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Rutgers Cancer Institute, The Ohio State University, National Cancer Institute, Massachusetts General Hospital, City Of Hope National Medical Center, Duke Medical Center, University of Southern California, Magee-Womens Hospital, University of Pittsburgh Medical Center, University of Washington, National Institutes of Health
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2890590134